Clin2
NCT07594145Possibly a fitNot yet recruiting

New therapies for heart and kidney problems in type 1 diabetes

Type 1 DiabetesT1D Heart FailureCardio-renal Vascular Function and FailureDiabetic Chronic Kidney Disease

Treatments studied

Part of Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.

This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
57 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have type 1 diabetes and have needed insulin within a year of diagnosis (or have certain tests showing type 1, not type 2)
  • You are between 18 and 75 years old
  • You have had type 1 diabetes for more than 10 years
  • Your average blood sugar (HbA1c) is between 7% and 10%
  • You have early signs of kidney damage or early heart failure (confirmed by specific tests)
  • You are not currently taking certain diabetes or heart medications (like GLP-1 agonists or aldosterone inhibitors)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06082063Recruiting· Phase 3
Reducing heart disease risk in type 1 diabetes

This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.

Copenhagen
NCT07026539Recruiting· Phase 4
Finerenone for heart and kidney health in type 2 diabetes

This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.

Aarhus N
NCT06727409Recruiting· Phase 4
Triple therapy for type 2 diabetes and kidney disease

This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.

Hong Kong
NCT07442448Enrolling by invitation· Phase 4
Study of Finerenone for heart and kidney health in diabetes

This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.

Taipei
NCT06217302Recruiting· Phase 3
Sotagliflozin for kidney protection in type 1 diabetes

This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.

Stanford, California
NCT06838416Recruiting
Study on finerenone for kidney health in type 2 diabetes

This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.

Suzhou, Jiangsu

Hear when a new Type 1 diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.